ArticleCureus2026
A Clinical-Operational Framework for Responsible Artificial Intelligence Use in Infection Risk Management Among Immunosuppressed Patients: A Technical Report.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Immunosuppressed patients carry a disproportionate infectious risk driven by underlying disease, biologic or immunomodulatory therapies, glucocorticoid exposure, comorbidities, latent infections, antimicrobial resistance, and fragmented follow-up. Artificial intelligence may support infection risk management by integrating clinical, microbiological, pharmacological, and operational data; however, it should not be implemented as an autonomous solution or a substitute for clinical judgment. This technical report proposes a clinical-operational framework for the responsible use of artificial intelligence in infection risk management among immunosuppressed patients. The framework includes seven domains: baseline infection risk stratification, screening and follow-up of latent infections, alerts for infectious deterioration, support for rational antimicrobial use, antimicrobial resistance surveillance, traceable clinical documentation, and continuous performance auditing. To reduce risks related to bias, false reassurance, alert fatigue, limited transportability, performance degradation, and excessive reliance on model outputs, the framework emphasizes local validation, human oversight, proportional explainability, institutional governance, longitudinal monitoring, adverse event review, and formal updating mechanisms. The objective is not to claim that artificial intelligence independently reduces infections or improves outcomes, but to define minimum conditions for its use as a supervised support tool within integrated programs for prevention, antimicrobial stewardship, patient safety, and risk management. This approach may be useful when prevention of latent tuberculosis, bacteremia, sepsis, opportunistic infections, and antimicrobial resistance requires coordinated clinical, microbiological, pharmacological, technological, quality, and audit processes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.